港股異動丨創科實業(0669.HK)升5% 領漲恆指成份股 獲投行唱好
格隆匯12月16日丨創科實業(0669.HK)今日高開走強,午後漲至5%領漲恆指成份股,報104.8港元,暫成交3.67億港元,總市值1920億港元。大摩報告指,行業今年下半年起需求強勁,電動工具製造商訂單沒有絲毫放緩的跡象,客户要求加快生產和擴大產能,預期未來行業仍然蓬勃發展,將創科實業目標價上調至125港元,評級增持,認為憑藉其執行力及市場地位,在全球不確定的宏觀環境下可進一步重估。日前麥格理更是上調創科目標價至134港元,指近期創科股價回落是入市好機會,預期隨着市場份額上升,未來3年毛利率將擴大。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.